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Background  Background 
• Multidrug resistance (MDR)  in HIV co-infected patients
• Increase of nosocomial transmission
• High case fatality rate
• MDR poorly documented in Sub-Saharan countries where 
majority of TB cases are HIV co-infected
• Emergence of MDR and Extreme-drug resistance (XDR)  
epidemics in Kwazulu Natal (Gandhi et al, Lancet.2006) 
• MDR-TB likely to be underestimated 
• North western Uganda 
- National adult HIV prevalence rate was of 6.7% in 2005
- Drug Susceptibility Testing survey in Uganda
○ 1996-97 (national): 0.5% MDR prevalence in new cases (NC) and 4.4% in previously treated cases (PTC)
○ 2000 (hospital-based study in Kampala): 4.7% MDR TB in NC, among those 70% HIV co-infected
• HIV and TB program supported by Médecins Sans Frontières in West Nile region (north-western Uganda) 
- MDR treatment available in Arua regional referral Hospital
Objectives Objectives Methods Methods
• Primary objective
- To measure the MDR prevalence in overall new smear 
patients and HIV co-infected ones
• Secondary objectives
- To describe the 1st line drug resistance patterns of NC and 
PTC
- To describe resistance to 2nd line drugs and XDR resistance 
among MDR-TB cases
• Cross-sectional survey of all consecutive smear positive patients in the TB centers of the Western Nile region 
• TB Case and Drug resistance definitions based on WHO/IUATLD standards definitions (WHO, 2006)
• Sample size: N = 400 NC 
• Laboratory procedures
- Collection of 2 sputum samples 
- Samples shipped to the Tropical Medical Institute (Antwerp)
○ Culture & DST 1st line on Lowenstein Jensen (LJ) or MGIT
○ DST 2nd line on agar 7H11: proportion method
Preliminary Preliminary results results






























Culture results Drug Sensitivity Testing results
13.6 3 - 0.0 0 0.6-6.3 2.1 3 MDR
4.5 1 - 0.0 0 0.1 - 4.8 0.7 1 HR
4.5 1 - 0.0 0 0.1 - 4.8 0.7 1 HRS
0.0 0 0.4 - 6.4 1.6 2 0.3 - 5.4 1.4 2 MonoE
0.0 0 4.4 - 14.6 8.1 10 3.7 - 12.4 6.9 10 MonoS
27.3 6 3.3 - 12.6 6.5 8 5.8 - 15.7 9.3 14 MonoH
0.0 0 - 0.0 0 - 0.0 0 MonoR
0.0 0 - 0.0 0 - 0.0 0 R+E+S
4.5 1 - 0.0 0 0.1 - 4.8 0.7 1 R+S
0.0 0 - 0.0 0 - 0.0 0 R+E
0.0 0 0.8 - 7.4 2.4 3 0.1 - 6.3 2.1 3 H+E+S
0.0 0 2.2 - 10.5 4.9 6 1.8 - 9.0 4.1 6 H+S
0.0 0 0.1 - 5.7 0.8 1 0.1 - 4.8 0.7 1 H+E
13.6 3 10.0 - 23.1 15.4 19 10.2 - 22.1 15.2 22 Any S
4.5 1 2.2 - 10.5 4.9 6 2.3 - 9.9 4.8 7 Any E
18.2 4 - 0.0 0 1.0 - 7.2 2.8 4 Any R
40.9 9 9.4 - 22.2 14.6 18 13.0 - 25.9 18.2 27 Any H
Other patterns
4.5 1 - 0.0 0 0.1 - 4.8 0.7 1 HRES
54.6 12 63.7-79.6 72.4 89 61.6-76.7 69.7 101 Full susceptible 
22 123 145 Nb of cases tested




• 86% NC and 36% being HIV co-infected 
 Low MDR-TB prevalence, only in PTC 
 No XDR 
• High rate of primary isoniazid resistance (14.6%)
• No difference of drug sensitivity in HIV+ and HIV- patients
Operational issues for the National program
• Low MDR rate: DST would be recommended only in failures of standard 1st line drugs regimens
• 4 months RH continuation phase might be not enough to assure patients with primary H resistance 
and might induce R resistance amplification





















































151 13 4 134 Total
2 1 0 1 Contaminated
18 2 3 13 Neg
131 10 1 120 Pos
Total Contaminated Neg Pos LJ
MGIT
•No XDR detected. 
•Of the 3 MDR patients : 1 was resistant to Ethionamide and 1 was resistant to Pyrazinamide
•A total of 169 patients were included in the DST survey (September 2007 - October 2008).
•Gender, age group and type of TB were not statistically different according to the HIV status.
Of the 169 patients included: 16 had ongoing culture analysis, 2 had non analysable sputum 
samples. 
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